Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q08AF3
UPID:
SLFN5_HUMAN
Alternative names:
-
Alternative UPACC:
Q08AF3; Q08AF2; Q8WU54; Q96A82
Background:
Schlafen family member 5 (SLFN5) is a protein that may play a crucial role in the differentiation of hematopoietic cells. This process is vital for the development of blood cells, indicating SLFN5's potential importance in maintaining healthy immune and circulatory systems.
Therapeutic significance:
Understanding the role of Schlafen family member 5 could open doors to potential therapeutic strategies. Its involvement in hematopoietic cell differentiation suggests that SLFN5 could be a target for enhancing blood cell production in various blood disorders.